{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:59:41Z","timestamp":1790359181381,"version":"4.1.0"},"reference-count":29,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2026,9,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the analgesic efficacy, adverse effect profile, incidence of acute pain crises and opioid-sparing effects of intravenous ketamine versus lignocaine infusions in patients with refractory cancer pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective, randomised, double-blind, controlled trial was conducted at Basavatarakam Indo American Cancer Hospital and Research Institute (October 2023\u2013January 2025). 66 adults with refractory cancer pain, defined as pain inadequately controlled despite an oral morphine equivalent (OME) dose exceeding 200 mg\/day, were randomised equally to receive either intravenous ketamine (0.3 mg\/kg\/hour) or intravenous lignocaine (2 mg\/kg\/hour), each administered as two 6-hour infusions separated by 12 hours. The primary outcome was effective pain relief, defined as a \u226550% reduction in pain severity. Secondary outcomes included adverse effects, acute pain crises during 6-week follow-up and postinfusion changes in OME dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Effective pain relief was achieved in 84.8% of the ketamine group and 72.7% of the lignocaine group (p=0.228). Both groups demonstrated significant reductions in OME dose from baseline (p&lt;0.01 for both), with no significant between-group difference (p=0.738). Adverse effects were significantly more frequent with ketamine than lignocaine (30.3% vs 9.1%; p=0.03). Acute pain crises during follow-up were numerically more common in the ketamine group (42.9% vs 29.2%), though this difference was not statistically significant (p=0.307).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ketamine and lignocaine demonstrated comparable analgesic efficacy and opioid-sparing effects in refractory cancer pain. Lignocaine, however, offers a more favourable safety profile with significantly fewer adverse effects, supporting its consideration as a preferred option in this clinical setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/spcare-2026-006327","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:20:12Z","timestamp":1790356812000},"page":"spcare-2026-006327","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of ketamine versus lignocaine intravenous infusion in refractory cancer pain: a prospective randomised double-blind controlled study"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0809-0701","authenticated-orcid":false,"given":"Sai Sowmya","family":"Pulluri","sequence":"first","affiliation":[{"name":"Pain and Palliative Medicine, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6841-6593","authenticated-orcid":false,"given":"Praveen Kumar","family":"Kodisharapu","sequence":"additional","affiliation":[{"name":"Pain and Palliative Medicine, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India"},{"name":"Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1428-680X","authenticated-orcid":false,"given":"Praneeth","family":"Suvvari","sequence":"additional","affiliation":[{"name":"Pain and Palliative Medicine, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India"},{"name":"Palliative Medicine, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basanth Kumar","family":"Rayani","sequence":"additional","affiliation":[{"name":"Onco-Anaesthesiology, Pain & Palliative Medicine, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7990-7397","authenticated-orcid":false,"given":"Pallavi","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Pain and Palliative Medicine, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3858-2552","authenticated-orcid":false,"given":"Kaduhole Shubha","family":"Pai","sequence":"additional","affiliation":[{"name":"Pain and Palliative Medicine, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8438-4449","authenticated-orcid":false,"given":"Dean","family":"George","sequence":"additional","affiliation":[{"name":"Pain and Palliative Medicine, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"2026092510200663000_spcare-2026-006327v1.1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm056"},{"key":"2026092510200663000_spcare-2026-006327v1.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-3047-4"},{"key":"2026092510200663000_spcare-2026-006327v1.3","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.21037\/apm.2019.09.09","article-title":"The use of ketamine in the management of refractory cancer pain in a palliative care unit","volume":"9","author":"Cheung","year":"2020","journal-title":"Ann Palliat Med"},{"key":"2026092510200663000_spcare-2026-006327v1.4","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2004.7.660"},{"key":"2026092510200663000_spcare-2026-006327v1.5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40122-023-00507-z","article-title":"Refractory Cancer Pain and Intrathecal Therapy: Critical Review of a Systematic Review","volume":"12","author":"Mercadante","year":"2023","journal-title":"Pain Ther"},{"key":"2026092510200663000_spcare-2026-006327v1.6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/PRBM.S44762","article-title":"Psychological therapies for the management of chronic pain","volume":"7","author":"Sturgeon","year":"2014","journal-title":"Psychol Res Behav Manag"},{"key":"2026092510200663000_spcare-2026-006327v1.7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy152"},{"key":"2026092510200663000_spcare-2026-006327v1.8","unstructured":"Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology in: journal of the national comprehensive cancer network volume 17 issue 8 (2019). Available: https:\/\/jnccn.org\/configurable\/content\/journals$002fjnccn$002f17$002f8$002farticle-p977.xml?t:ac=journals%24002fjnccn%24002f17%24002f8%24002farticle-p977.xml [Accessed 28 Mar 2025]."},{"key":"2026092510200663000_spcare-2026-006327v1.9","first-page":"27","article-title":"Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration","volume":"16","author":"Kronenberg","year":"2002","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2026092510200663000_spcare-2026-006327v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(06)80004-7"},{"key":"2026092510200663000_spcare-2026-006327v1.11","doi-asserted-by":"crossref","unstructured":"Nath TS . n.d. Case Report: Effectiveness of Low-Dose Ketamine Infusion in Opioid Refractory Cancer Pain. Cureus PubMed Central PMCID. doi:10.7759\/cureus.31662","DOI":"10.7759\/cureus.31662"},{"key":"2026092510200663000_spcare-2026-006327v1.12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.21037\/apm.2018.01.01","article-title":"The use of ketamine in a palliative-supportive care unit: a retrospective analysis","volume":"7","author":"Mercadante","year":"2018","journal-title":"Ann Palliat Med"},{"key":"2026092510200663000_spcare-2026-006327v1.13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/SPC.0000000000000262","article-title":"Ketamine for cancer pain: what is the evidence?","volume":"11","author":"Jonkman","year":"2017","journal-title":"Curr Opin Support Palliat Care"},{"key":"2026092510200663000_spcare-2026-006327v1.14","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/pme.12182","article-title":"Ketamine for pain in adults and children with cancer: a systematic review and synthesis of the literature","volume":"14","author":"Bredlau","year":"2013","journal-title":"Pain Med"},{"key":"2026092510200663000_spcare-2026-006327v1.15","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2011.0244"},{"key":"2026092510200663000_spcare-2026-006327v1.16","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1089\/jpm.2020.0622","article-title":"Parenteral Lidocaine for Complex Cancer Pain in the Home or Inpatient Hospice Setting: A Review and Synthesis of the Evidence","volume":"24","author":"Chong","year":"2021","journal-title":"J Palliat Med"},{"key":"2026092510200663000_spcare-2026-006327v1.17","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/pm\/pny031","article-title":"Intravenous Lidocaine Provides Similar Analgesia to Intravenous Morphine for Undifferentiated Severe Pain in the Emergency Department: A Pilot, Unblinded Randomized Controlled Trial","volume":"20","author":"Clattenburg","year":"2019","journal-title":"Pain Med"},{"key":"2026092510200663000_spcare-2026-006327v1.18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1089\/jpm.2018.0257","article-title":"Lidocaine for Cancer Pain in Adults: A Systematic Review and Meta-Analysis","volume":"22","author":"Lee","year":"2019","journal-title":"J Palliat Med"},{"key":"2026092510200663000_spcare-2026-006327v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2007.12.023"},{"key":"2026092510200663000_spcare-2026-006327v1.20","doi-asserted-by":"publisher","DOI":"10.1007\/s005200050242"},{"key":"2026092510200663000_spcare-2026-006327v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.12.010"},{"key":"2026092510200663000_spcare-2026-006327v1.22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.37.4.378"},{"key":"2026092510200663000_spcare-2026-006327v1.23","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"2026092510200663000_spcare-2026-006327v1.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.2003.00330.x"},{"key":"2026092510200663000_spcare-2026-006327v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(00)00194-9"},{"key":"2026092510200663000_spcare-2026-006327v1.26","doi-asserted-by":"crossref","first-page":"10499091261452628","DOI":"10.1177\/10499091261452628","article-title":"Retrospective Chart Review Evaluating Efficacy and Tolerability of Ketamine Continuous Infusion for Cancer-Related Pain","volume":"0","author":"Atayee","year":"2026","journal-title":"Am J Hosp Palliat Care"},{"key":"2026092510200663000_spcare-2026-006327v1.27","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000169673.57062.40"},{"key":"2026092510200663000_spcare-2026-006327v1.28","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/15360288.2019.1704339","article-title":"A Multi-Centered Case Series Highlighting the Clinical Use and Dosing of Lidocaine and Mexiletine for Refractory Cancer Pain","volume":"34","author":"Atayee","year":"2020","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2026092510200663000_spcare-2026-006327v1.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(01)00340-2"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2026-006327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:20:16Z","timestamp":1790356816000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2026-006327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":29,"alternative-id":["10.1136\/spcare-2026-006327"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2026-006327","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}